60 DEGREES PHARMACEUTICALS, INC.
SXTP evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $3.2M
- Next Catalyst:
- Patent_Expiry · Dec 2, 2035
What it means
What to watch
Prepared research question
What matters most for SXTP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SXTP
60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company developing and commercializing new medicines for vector-borne diseases, with a primary focus on tafenoquine (ARAKODA®) for babesiosis and malaria.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials · 1 catalyst for 60 DEGREES PHARMACEUTICALS, INC..
60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company developing and commercializing new medicines for vector-borne diseases, with a primary focus on tafenoquine (ARAKODA®) for babesiosis and malaria.
- Cash & equivalents of $1.0M as of 2026-06-30 [sec].
- Total revenue of $0.2M and net income of -$2.3M for the quarter ended 2026-06-30 [sec].
- Shareholders' equity of $2.6M and total debt of $0.2M as of 2026-06-30 [sec].
- Net product revenues increased approximately 106% to ~$208K in Q2 2026 from ~$101K in Q2 2025 [news · 2026-08-14].
- Company intends to submit an application for a Commissioner's National Priority Review Voucher if interim/final analysis of the tafenoquine babesiosis trial supports an sNDA submission before Q1 2028 [news · 2026-06-03].
What works
- Net product revenues grew ~106% year-over-year in Q2 2026, indicating increasing commercial traction [news · 2026-08-14].
- All three patients in an expanded use clinical trial were cured of babesiosis after tafenoquine treatment, confirming a high cure rate in immunosuppressed patients [news · 2026-03-11].
- The B-Free chronic babesiosis trial cleared initial safety review and advanced after a DSMB recommendation [news · 2026-07-01].
- Company estimates a total addressable market for ARAKODA in human babesiosis of up to $245 million annually, with no existing FDA-approved treatment [news · 2025-07-15].
What to weigh
- Cash position is low at $1.0M as of 2026-06-30, which may limit operational runway [sec].
- Net income was negative (-$2.3M) for the quarter ended 2026-06-30, reflecting ongoing operating losses [sec].
- The tafenoquine babesiosis program is still in Phase 2; regulatory and clinical risks remain, including the outcome of the ongoing interim analysis [news · 2026-07-09].
- Company has only 23 patients enrolled in the pivotal babesiosis trial as of July 2026, a small sample size that may limit statistical power [news · 2026-07-09].
From the filings
Quoted directly from source documents.
Net product revenues increased ~106% in Q2 2026
“Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026”
News · August 14, 2026
All three patients cured in expanded use babesiosis trial
“All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients”
News · March 11, 2026
Company intends to apply for a National Priority Review Voucher if data supports sNDA before Q1 2028
“The Company intends to submit an application for a Commissioner's National Priority Review Voucher if the outcome of any interim and/or final analysis of the Company's randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis supports moving forward with a New Drug Application submission to the U.S. Food and Drug Administration ("FDA") before the end of the first quarter of 2028.”
News · June 3, 2026
Catalyst timeline
- 2035-12-02 · Patent_Expiry · TAFENOQUINE SUCCINATE — Patent_Expiry: NDA210607 — Patent expiry for tafenoquine succinate; may affect future exclusivity and market competition.
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash & equivalents of $1.0M as of 2026-06-30 may limit ability to fund ongoing operations and trials [sec].
- Negative net income — Net loss of $2.3M in Q2 2026 indicates the company is not yet profitable [sec].
- Small trial enrollment — Only 23 patients enrolled in the pivotal babesiosis trial as of July 2026, which may affect statistical power [news · 2026-07-09].
- Regulatory and clinical uncertainty — The tafenoquine babesiosis program is still in Phase 2; outcomes of interim analysis and FDA interactions are unknown [news · 2026-07-09].
What to watch
- Interim analysis data from the tafenoquine babesiosis trial, to be presented on October 6, 2026 [news · 2026-10-01].
- Decision on whether to submit an sNDA for tafenoquine in babesiosis before Q1 2028 [news · 2026-06-03].
- Progress of the B-Free chronic babesiosis study (Phase 2, up to 100 patients) [news · 2025-11-21].
- Cash burn rate and any new financing or partnership announcements given the low cash position [sec].
Sources: Catalysts · News · Generated October 3, 2026 · How we verify sources →
Run 60 DEGREES PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available 60 DEGREES PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.67 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~3336d
1 buy · 0 sells (180d)
Catalysts
Regulatory
Financials
Short Interest
as of May 22, 2026- % of float
- 5.5%
- Days to cover
- 0.6
- Shares short
- 142,704
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SXTP short interestGovernance
Frequently asked questions
What is the AI investment thesis for 60 DEGREES PHARMACEUTICALS, INC.?
60 Degrees Pharmaceuticals, Inc. (SXTP) is a biopharmaceutical company developing and commercializing new medicines for vector-borne diseases, with a primary focus on tafenoquine (ARAKODA®) for babesiosis and malaria.
What is 60 DEGREES PHARMACEUTICALS, INC.'s next catalyst?
60 DEGREES PHARMACEUTICALS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA210607" — expected December 2, 2035.
Who is the CEO of 60 DEGREES PHARMACEUTICALS, INC.?
Dr. Geoffrey Stuart Dow Ph.D. is the chief executive officer of 60 DEGREES PHARMACEUTICALS, INC. (SXTP).
Where is 60 DEGREES PHARMACEUTICALS, INC. headquartered?
60 DEGREES PHARMACEUTICALS, INC. (SXTP) is headquartered in Washington, DC, United States.
What therapeutic areas does 60 DEGREES PHARMACEUTICALS, INC. focus on?
60 DEGREES PHARMACEUTICALS, INC. develops therapies across Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.